Search
DiaMedica Therapeutics Inc
DMACAdd to Watchlist
6.735USD
-0.085-1.25%
Close 07-24 16:00（ET）Quotes delayed by 15 min
362.90MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-24The current earnings forecast score of DiaMedica Therapeutics Inc is 8.00, ranking 168 out of 386 in the Biotechnology & Medical Research industry. The average price target is 13.00, with a high of 25.00 and a low of 11.00.
Analyst Rating
Based on
5
analysts
Buy
Current Rating
15.500
Target Price
+127.27%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
DiaMedica Therapeutics Inc
DMAC
5
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Insmed Inc
INSM
23
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is DiaMedica Therapeutics Inc's price target?
Analysts forecast that DiaMedica Therapeutics Inc's price target is USD 13.00, with the highest forecast at USD 25.00 and the lowest forecast at USD 11.00.
How have DiaMedica Therapeutics IncDMAC's recent earnings per share performed?
The market expectation was USD -0.19, while DiaMedica Therapeutics IncDMAC's earnings per share (EPS) for the previous quarter was USD -0.17. EPS for the next quarter is expected at USD -0.20.
What is the analyst rating for DiaMedica Therapeutics Inc?
Based on the ratings of DiaMedica Therapeutics Inc's stock from 5 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.